Novartis could take $750M hit for recalls; Greek pharmacist becomes medicine hunter;

> The recent Novartis ($NVS) recall of OTC medicines could cost $560 million to $750 million in lost sales and productivity, a Wall Street analyst says. More

> A pharmacist in Athens "spends hours each day pleading with drugmakers, wholesalers and colleagues to hunt down medicines." Story

> NantWorks LLC plans to spend $85 million to renovate Pfizer's ($PFE) Terra Haute, IN, manufacturing plant for production of critical-care injectable and cancer drugs. News

> The shortage of calcitriol, manufactured by Abbott Labs ($ABT), is now resolved. FDA listing

> A 69-acre, 1,300-job AstraZeneca ($AZN) manufacturing plant in Loughborough, U.K., closed in December, is being marketed "more broadly" after talks with Chinese pharma investors appear to have stalled. Article

> Andrea Zobelhas joined Marken as a senior director, responsible for the company's network of clinical trial supply depots when qualified. Release

> Some 150 staff members of Almac's Clinical Services business unit have moved into a new 30,000-square-foot building, consolidating services for clients in more than 100 countries. News

> A team effort by the World Bank, the U.K. Department for International Development, and the Small Industries Development Bank of India has helped more than 200 Indian drugmakers become export-ready GMP practitioners. Article

> Catalent Pharma Solutions is remodeling a former GE Healthcare building in Wisconsin and is planning to move in by year's end, vacating its current site. Story

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.